Alexion Pharmaceuticals Inc (ALXN)

109.62 +0.09  +0.08% NASDAQ Nov 22, 12:39 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
02/04/2020 08:00 EST Misc Alexion Pharmaceuticals Inc Fourth Quarter Earnings Conference Call in 2019
02/04/2020 Earnings Alexion Pharmaceuticals Inc Fourth Quarter Earnings in 2019 Release
10/23/2019 08:00 EDT Misc Alexion Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2019
10/23/2019 Earnings Alexion Pharmaceuticals Inc Third Quarter Earnings in 2019 Release
07/24/2019 08:00 EDT Misc Alexion Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2019
07/24/2019 Earnings Alexion Pharmaceuticals Inc Second Quarter Earnings in 2019 Release
05/14/2019 Misc Alexion Pharmaceuticals Inc Annual General Meeting in 2018
04/25/2019 08:00 EDT Misc Alexion Pharmaceuticals Inc First Quarter Earnings Conference Call in 2019
04/25/2019 Earnings Alexion Pharmaceuticals Inc First Quarter Earnings in 2019 Release
02/06/2019 Misc Alexion Pharmaceuticals Inc Annual Report in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.alexion.com
  • Investor Relations URL: http://ir.alexionpharm.com/
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Large Cap/Blend
  • Next Earnings Release: Feb. 04, 2020
  • Last Earnings Release: Oct. 23, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Top Fund Holders

Symbol Name Weighting
FIJYX Fidelity Advisor® Biotechnology Z 8.07%
HQL Tekla Life Sciences Investors 3.67%
URLGX Columbia Select Large Cap Growth R 3.54%
IBB iShares Nasdaq Biotechnology ETF 3.46%
FBT First Trust NYSE Arca Biotech ETF 3.31%
HQH Tekla Healthcare Investors 3.04%
FBIOX Fidelity® Select Biotechnology 2.65%
FXH First Trust Health Care AlphaDEX® ETF 2.26%
FACTX Fidelity Advisor® Health Care M 2.05%
FSPHX Fidelity® Select Health Care 1.98%
XBI SPDR® S&P Biotech ETF 1.55%
THISX T. Rowe Price Health Sciences I 1.45%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.